Related tags: remote patient monitoring, remote monitoring, decentralized testing, wearable devices, blood pressure function sanitize_gpt_value2 (gptValue) {var vOut = “”; var aTags = gptValue.split(‘,’); var reg = new RegExp( ‘\\ W +’, “g”); for(var i = 0; i
Smart Meter’s iBloodPressure cellular sphygmomanometer has a 4/5G LTE communication chip that enables users to automatically transmit patient results to a remote patient monitoring (RPM) portal without using WiFi, docking stations, synchronization, apps or smartphones. The device can provide a high degree of convenience for patience and higher efficiency for clinical trial teams.
Outsourced Pharmaceuticals (OSP) discussed the technology with Smart Meter CEO Brahim Zabeli, who explained how the technology works and the advantages it provides for sites, sponsors and patients.
OSP: Please share your views on the development of wearable devices in clinical research-that is, how they increase complexity, how to measure different vital signs, the different functions that appear, etc.
BZ: In the past five years, many devices have appeared, providing consumers with many fashionable choices and opportunities to manage my health. However, there is a difference between clinical-grade health monitoring solutions and non-regulated consumer devices.
The Center for Medicare and Medicaid Services (CMS) has issued guidelines stating that only devices approved for medical use by the U.S. Food and Drug Administration (FDA) can be reimbursed under the specific CPT code of remote physiological monitoring (RPM). This is where health care is really improved.
With the help of RPM-approved devices such as iGlucose and iBloodPressure, healthcare providers can view real-time data and intervene if long-term and acute care patients are experiencing severe out-of-range attacks. These devices can help reduce emergency visits, reduce emergency visits, hospitalization and rehospitalization, and increase drug titers, thereby further reducing complications and comorbidities.
Smart Meter’s FDA-approved devices have been clinically verified and tested to ensure accuracy and safety. These devices have been shown to improve the prognosis of patients with HbA1c and hypertension. In addition, the communication mode within the smart meter device reduces many technical burdens on patients.
Thanks to the built-in cellular functions of iGlucose and iBloodPressure devices, patients do not need to perform any synchronization, upload operations, and do not require a smartphone or Wi-Fi connection. Devices must be smarter and able to provide care for all people, including underserved people, and lack access to mainstream technology and medical care.
OSP: How does the impact of the pandemic on clinical research make your work in remote monitoring technology more important?
BZ: Some of our research partners and providers are concerned about how to provide medical services to people who are underserved and do not have access to mainstream technology and medical care. They proved that technologies like Smart Meter already exist, can work and are inexpensive, and can provide the same or even better level of care for patients who have historically been unable to access cutting-edge medical services.
In a recent study (the EMBRAACE study conducted by Dr. M. Osman of Howard University), a small cohort of Medicaid patients in Washington, DC showed that the use of iGlucose can reduce A1C by about 1%. That may mean the difference between having to take more expensive drugs, amputation and other complications or hospitalization.
The latest technological advancements in RPM are affecting and improving the lives of our most vulnerable and underserved people.
OSP: Can you share some features and functions that make it more suitable for researchers than traditional BP monitors or other digital/WiFi-enabled devices?
BZ: The most important feature of Smart Meter’s iBloodPressure device is cellular connectivity and synchronized patient data immediately sent to the provider. They no longer need to rely on patient records, download, sync, or bring their equipment or logs to the office to get results.
The patient only needs to perform the test to seamlessly send the data to the provider dashboard without any patient intervention. This works because the provider can now get the data immediately and can intervene between visits (if necessary).
OSP: Would you like to add the iBloodPressure monitor that we did not mention above?
BZ: Smart Meter believes that it is very important to have a strong customer support team to respond quickly to our customers and end users. We have technical support and data operation teams to solve all possible problems. Since our establishment in 2015, we have served thousands of patients on behalf of our channel partners, and our expertise in leading innovation in this field is unparalleled.
We can help expand new RPM companies, emerging and existing provider and payer programs, and research projects within a few weeks. Customers can rest assured that we will keep the best interests in mind and equip them with the ability to quickly and sustainably start successful RPM practices.
OSP: Do you want to tell us whether there are other products used for clinical research in our works?
BZ: Smart Meter has many other projects that are studying new parameters. We encourage readers to follow Smart Meter on LinkedIn and our website (www.SmartMeterRPM.com) to get all the latest information about our products, RPM growth and adoption, and expense reimbursement.
Copyright-Unless otherwise stated, all content on this website is ©2021-William Reed Business Media Ltd-All rights reserved-For complete details on the use of materials on this website, please refer to the terms and conditions.
Related topics: clinical development, clinical evolution, patient-centered, medical equipment, data management, phase III-IV, phase I-II
Immune monitoring has become an important strategy to understand, predict and monitor the immune system’s response to therapeutic intervention.
This article briefly outlines why automation is absolutely necessary for clinical trial success.
During times of crisis worldwide, there is an increasing demand for accelerated COVID19 vaccination. Regardless of the great progress made recently…
In order for the research to be successful, the data collected must be correct and complete. To be correct and complete, the form must be carefully planned and meticulous.
Free newsletter subscription Sign up for our free newsletter and send the latest news directly to your inbox
Post time: Feb-19-2021